X4 reports Phase II data for WHIM syndrome candidate

X4 Pharmceuticals Inc. (Cambridge, Mass.) reported preliminary data from five evaluable patients with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome

Read the full 201 word article

User Sign In